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Correlation of clinical and molecular
features in spinal bulbar muscular atrophy
ABSTRACT
Objectives: To characterize the clinical and genetic features of spinal bulbar muscular atrophy
(SBMA), a rare neurodegenerative disorder caused by the expansion of a CAG repeat in the first
exon of the androgen receptor gene, in the United Kingdom.
Methods: We created a national register for SBMA in the United Kingdom and recruited 61
patients between 2005 and 2013. In our cross-sectional study, we assessed, by direct question-
ing, impairment of activities of daily living (ADL) milestones, functional rating, and subjective dis-
ease impact, and performed correlations with both CAG repeat size and degree of somatic
mosaicism. Ten patients were deceased, 46 patients participated in the study, and 5 declined.
Results: Subjects had an average age at onset of 43.4 years, and weakness onset most frequently
occurred in the lower limbs (87%). Impaired mobility was the most frequently reported problem by
patients, followed by bulbar dysfunction. Age distribution of the impairment of ADL milestones
showed remarkable overlap with a Japanese study. We have identified a significant correlation
between the number of CAG repeats and both age at onset and ADL milestones. Somatic mosa-
icism also showed a correlation with CAG expansion size and age at onset.
Conclusions: Clinical features in SBMA show a substantial overlap when comparing populations
with different genetic backgrounds. This finding has major implications, because multicenter
trials will be necessary to obtain sufficient power in future clinical trials. Clinical-genetic correla-
tions are strong in SBMA and should inform any clinical research strategy in this condition.
Neurology® 2014;82:2077–2084
GLOSSARY
ADL 5 activities of daily living; ALS 5 amyotrophic lateral sclerosis; ALSFRS-R 5 revised Amyotrophic Lateral Sclerosis
Functional Rating Scale; AR 5 androgen receptor; MI 5 mosaicism index; SBMA 5 spinal bulbar muscular atrophy.
Spinal bulbar muscular atrophy (SBMA), also known as Kennedy disease, is a rare progressive
neurodegenerative disorder caused by the expansion of a CAG repeat in the first exon of the gene
encoding the androgen receptor (AR), which lies on the X chromosome.1,2 SBMA is character-
ized by the loss of lower motor neurons leading to progressive weakness in the limbs and in the
bulbar musculature.1,3,4 The disease also shows a peripheral nerve sensory involvement and signs
of androgen insensitivity, which manifest with gynecomastia and reduced fertility in males.5,6
The CAG expansion gives rise to a polyglutamine repeat, similar to various other neurologic
disorders, termed “polyglutamine diseases.”7 The disease manifests when the number of AR
CAG repeats lies above the threshold of 38; as in other polyglutamine diseases, clinical features,
such as age at disease onset, are inversely linked to the length of the expansion size.3,8 Accumu-
lation of misfolded protein is found in patients’ motor neurons and is likely to have a role in
disease.9 Nonetheless, experiments on SBMAmouse models have shown that the presence of the
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CAG expanded repeat is not sufficient to cause
disease and that the presence of androgens is
crucial for the disease to develop—which ex-
plains why women carrying the mutation are
generally asymptomatic or manifest only mild
symptoms, even when homozygous for the AR
expansion.10–13
These findings have led to phase 2 clinical
trials using agents targeting androgen synthesis
and regulation.14,15 Unfortunately, no signifi-
cant effects on disease course were detected;
however, more sensitive outcome measures
and larger numbers were thought to be essen-
tial to better assess therapeutic interventions in
this disease.14–16 To conduct such clinical trials
on larger numbers of patients, a multicenter
approach is necessary.
SBMA is a rare disease, and single medical
centers in the United Kingdom are unlikely
to follow more than 4 patients. We therefore
created the first UK National Register for
SBMA and here we present clinical and genetic
information from 56 patients with SBMA and
comparisons with the only 2 previous large
clinical studies of SBMA, performed in Japan
and in the United States.3,4 Our results contrib-
ute to the definition of SBMA clinical history
and highlight the homogeneity of SBMA clin-
ical features in populations with different geo-
graphic and genetic backgrounds; this has
important implications for future multicenter
studies.
METHODS Patients and evaluation. Patients diagnosed
with SBMA were recruited through the British Neurological Sur-
veillance Unit, an established collaborative research system run by
the Association of British Neurologists. Consent was obtained
directly from patients. Patients included in the register are fol-
lowed in numerous centers across the United Kingdom, and
DNA samples were obtained from local genetic laboratories with
full informed consent where available. All participants in this
study were interviewed by one research nurse specialist by tele-
phone, with the exception of 2 patients who compiled the ques-
tionnaire by writing because of speech difficulties. There were no
missing data for any of the patients who agreed to undergo inter-
view. The questionnaire was composed of 54 questions designed
to require a “yes/no” answer. Five questions, addressing the initial
symptoms and major complaints, required a descriptive answer.
For deceased patients, only age at onset and age at death data were
included in the study.
Standard protocol approvals, registrations, and patient
consents. The study was approved by the National Research
Ethics Service of the UKNational Health Service and local ethical
committees. All patients received a patient information leaflet and
signed a written informed consent form.
AR CAG repeat fragment sizing. Genomic DNA was ex-
tracted from patient peripheral blood leukocytes using a FlexiGene
DNA kit (Qiagen, Venlo, the Netherlands). AR alleles were ampli-
fied by PCR using GoTaq DNA polymerase (Promega, Madison,
WI) and a FAM-label introduced by the forward primer. The
primers used were previously described.3 PCR products were
checked on a 4% (w/v) agarose gel and then electrophoresed on
an ABI 3730xl DNA analyzer with a LIZ-500 size standard (Applied
Biosystems, Foster City, CA). Fragment analysis was performed with
GeneMapper software (version 4.0; Applied Biosystems).
AR CAG repeat sequencing. The CAG repeat regions of pa-
tients with SBMA were amplified by PCR using REDtaq Poly-
merase (Sigma, St. Louis, MO) and the primers specified by
La Spada et al.2 (59-GCCTGTTGAACTCTTCTGAGC-39
and 59-GCTGTGAAGGTTGCTGTTCCTC-39). Reaction
mixtures were made in accordance with the manufacturer’s
instructions and a touchdown PCR protocol was used to reduce
Table General study demographics and disease onset features
No. of living patients in register (participated in study) 51 (46)
No. of deceased patients 10
Age at onset, y, mean (range) 43.4 (14–75)
Age at study, y, mean (range) 57.6 (19–75.9)
Years of disease duration from onset, mean (range) 16.6 (0–43)
CAG repeats, mean (range) 45.5 (40–53)
Positive family history, % 71.7
Diagnosis before symptoms, % 10.8
Patients seen regularly by a neurologist, % 87
Interval between visits, mo, median (range) 12 (2–24)
Patients who underwent a muscle biopsy, % (n) 28.3 (13)
Symptom that brought to medical attention, % (n)
Bulbar weakness 6.7 (3)
Upper extremities weakness 22.2 (10)
Lower extremities weakness 86.7 (39)
Breast enlargement 6.7 (3)
Cramps 6.7 (3)
Tremor 13.3 (6)
Weakness district onset, % (n)
Bulbar 6.7 (3)
Upper extremities 26.7 (12)
Lower extremities 88.9 (40)
Symmetricity and dominance, %
Asymmetrical onset 54.5
Dominant side onset where asymmetrical onset 70.8
Patients who received an alternative diagnosis, % (n) 30 (14)
Muscle biopsy 35.7 (5)
Spinal muscular atrophy 42.9 (6)
Muscular dystrophy 21.4 (3)
Parkinson disease 14.3 (2)
Myasthenia gravis 14.3 (2)
Amyotrophic lateral sclerosis 7.1 (1)
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nonspecific amplification. PCR cycling conditions were
30-second denaturing at 95°C, 30 seconds of annealing at 72°
C (reduced by 0.5°C every cycle for 24 cycles), 40 seconds for
extension at 72°C, then followed by a further 10 cycles of
30-second annealing at 95°C, 30-second annealing at 60°C,
and 40 seconds of extension at 72°C. The PCR product was
purified from the amplification mixture using microCLEAN
PCR clean-up kit (Microzone, Haywards Heath, UK), and the
repeat region of interest was sequenced using ABI Prism BigDye
Terminator Cycle Sequencing Ready Reaction kit version 1.1
(Applied Biosystems, Foster City, CA). Fifteen-microliter
sequencing reactions comprised 5 to 20 ng of DNA template,
1 mL BigDye mix, 5 mL Better Buffer (Microzone), 5 pmol of
either the forward or reverse sequencing primer (same as PCR
primers), 1 mL betaine, and were made up with an appropriate
volume of nuclease free water. Cycling parameters for sequencing
were set to 300 seconds at 95°C, 30-second denaturing at 96°C,
15-second annealing at 55°C, 240-second extension at 60°C, and
repeated for 35 cycles. Sequences were precipitated in ethanol,
ethylenediaminetetraacetic acid, and sodium acetate solution and
further washed in 70% ethanol. Sequences were determined on a
3730xl DNA Analyzer capillary sequencer (Applied Biosciences)
and analyzed with Geneious sequencing software (Biomatters,
Auckland, NZ).
Evaluation of mosaicism. Fluorescent PCR fragment sizing
was analyzed using Peak Scanner v1.0. The areas of the major
peak and of all peaks corresponding to larger fragment sizes were
calculated. Only peaks with an area .2% of major peaks were
considered. We obtained a mosaicism index (MI) by dividing the
area corresponding to all minor peaks by the major peak area. Clon-
ing of the CAG repeat was performed as previously described.17
Statistical analysis. Linear regression analysis was performed
using GraphPad Prism v5.03 (GraphPad Software, La Jolla, CA).
RESULTS Clinical and genetic background. Since
2005, 61 patients with SBMA have consented to take
part in the UK National Register for SBMA. Of a total
of 51 living patients, 46 participated in the current
study, of whom 44 were of European descent and 2
were of Indian descent. Five patients declined to
undergo interview because of lack of interest. The
available genetic and clinical data from 10 deceased pa-
tients were also included where relevant. The average
age at the time of study was 57.6 years, and the average
time from disease onset was 16.6 years. A positive fam-
ily history was reported in 71.7% of participants, and
10.8% received a genetic diagnosis before symptom
onset. The majority of patients (87%) were followed
regularly by a neurologist, with yearly visits in most
cases (table).
Disease onset and clinical presentation. The average age
of disease onset was 43.4 years (range 14–75 years).
Lower limb weakness was the most common present-
ing symptom (86.7%), followed by upper limb weak-
ness (22.2%), tremors (13.3%), and bulbar weakness
(6.7%) (table). Onset of weakness was asymmetrical
in 54.5% of cases, and in 70.8% of asymmetrical
onset cases, weakness occurred on the dominant side
first. Many patients (28.3%) underwent a muscle
biopsy and 30% of patients received an alternative
diagnosis in the first instance. The most frequent
alternative diagnosis was spinal muscular atrophy
(42.9%), followed by muscular dystrophy, Parkinson
disease, myasthenia gravis, and amyotrophic lateral
sclerosis (ALS) (table).
Disease progression and activities of daily living
milestones. To gain information on the clinical course
of the disease, we investigated the onset of decline in
Figure 1 Age distribution of ADL milestones
For each milestone, median age, 10th and 90th percentile (box), and range (whiskers) of age
are plotted (A). Median age of ADL from the UK SBMA cohort described in this study (green)
and a Japanese SBMA cohort3 (pink) are plotted (B). ADL5 activities of daily living; SBMA 5
spinal bulbar muscular atrophy; UK 5 United Kingdom.
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activities of daily living (ADL). The earliest deficit
noticed by patients was hand tremor at a median age
of 35 years, followed by muscle weakness at a median
age of 43. The sequential use of walking aids (handrail,
cane, frame, and wheelchair), bulbar-related ADL
milestones (dysarthria and dysphagia), and erectile
dysfunction were reported between the ages of 50 and
60 years (figure 1A). Only one patient had undergone
gastrostomy. Death occurred in 10 patients at a median
age of 79. To investigate whether the SBMA course
overlaps in cohorts with different genetic backgrounds,
we plotted the median age of ADLmilestone data from
our study together with data from a large cohort (n 5
223) described in Japan3 (figure 1B), and the data
showed remarkable similarity.
Characteristic motor symptoms such as muscle
cramps and muscle twitching were respectively
described in 76.1% (n 5 35) and 84.7% (n 5 39)
of patients, at a median age of 39.4 and 41.8 years.
Onset of sensory symptoms, described as numbness
or tingling, was noticed by 58.7% (n5 27) of patients,
at a median age of 50 years. Breast enlargement was
described by 73.9% of patients at a median age of 39.1
years (figure e-1 on the Neurology® Web site at
Neurology.org).
Cross-sectional evaluation: Self-assessment testing,
disease impact, and comorbidity. Participants were eval-
uated at the time of study using the revised ALS
Functional Rating Scale (ALSFRS-R), devised to
monitor progression of motor neuron disease, which
considers bulbar, limb, and respiratory weakness.18
For each item, scores range from 0 to 4, with 4 being
unaffected. The average score was 38.2 (range 18–
48), with 48 being the maximum possible score.
The most severely affected activities related to mobil-
ity, walking and climbing stairs, and these items had
an average score of 2.6 and 1.8, respectively. Bulbar
and upper limb linked activities followed; the least
affected items were those related to the respiratory
function of patients (figure 2A). We have plotted
our results in parallel with results from a cross-
sectional study and show a similarity between the
cohorts19 (figure e-2).
We also assessed the major subjective disease-
related disabilities by asking participants to state their
3 major disabling issues. Impairment of mobility was
the most frequent complaint (31%), followed by mus-
cle weakness (22%), swallowing problems (14%),
speech problems (7%), hand tremors (7%), breathing
problems (5%), fatigue (3%), cramps (3%), and erec-
tile dysfunction (3%) (figure 2B).
The comorbidity in our cohort consisted of 18%
with diabetes and 28% had had infectious pneumonia.
CAG sizing and clinical correlations. All participants
underwent genetic testing in different regional UK
clinical genetics departments. Given the variability
that can occur in performing fragment analysis,20
we used data on CAG expansion sizing only when
performed in our institute (n5 37) or in laboratories
where the fragment analysis PCR was normalized by
using a reference sample (n 5 2) in order to obtain
homogeneous data. Mean repeat size from 39 indi-
viduals was 46.03, ranging between 40 and 53.
We plotted the CAG repeat size in relation to age at
disease onset and age at onset for the major ADL mile-
stones and clinical features and performed regression
analysis. CAG repeat size significantly inversely correlated
Figure 2 Cross-sectional assessment of spinal bulbar muscular atrophy
disability and symptoms
Mean score value and score range for all items of the Amyotrophic Lateral Sclerosis Func-
tional Rating Scale (ALSFRS) are plotted (A). Participants were asked to define the 3 major
problems caused by disease, and results are plotted (B).
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with age at disease onset, use of a handrail, use of a cane,
use of a wheelchair, and muscle weakness (p 5 0.0035)
(figure 3). Other clinical features, including hand tremor,
muscle twitching, muscle cramps, sensory symptoms,
dysarthria, dysphagia, breast enlargement, and erectile
dysfunction showed trends for an inverse correlation,
but did not reach statistical significance (figure e-3).
To assess whether CAG expansion size influences
disease progression, we correlated CAG repeat number
with time intervals occurring between ADL milestones
and found no significant association (figure e-4).
Evaluation of mosaicism and clinical correlations. Somatic
instability of the repeat expansion is a feature common
to the majority of microsatellite expansion disorders
and has been shown to occur in numerous tissues in
SBMA.21 Therefore, we investigated whether the
degree of somatic mosaicism measured in blood corre-
lated with disease clinical features.
When assessing the repeat size, using both frag-
ment analysis and sequencing, we observed a major
peak and 2 to 3 smaller peaks corresponding to both
larger and smaller repeat expansions, as previously
described (figure e-5B).21 All patients presented peaks
on both sides of the major peak, while all tested sam-
ples with normal repeat range showed only peaks
corresponding to smaller sizes (figure e-5A), which
have previously been suggested to be PCR artifacts.21
To confirm the origin of the observed peaks, we PCR
amplified the CAG expanded repeats and cloned and
then sequenced the products, which revealed a single
peak suggesting that sequencing produces no artifacts
(figure 4A). We then reamplified the cloned product
by PCR and observed the appearance only of peaks
corresponding to smaller size repeats, thus confirming
(1) that PCR amplification indeed contributes to gen-
erating smaller repeats by slippage, and (2) that the
larger size peaks represent genuine somatic instability
(figure 4A). Therefore, we considered only the peaks
(1) corresponding to amplicons larger than the major
peak, and (2) that had an area of .2% of the major
peak. The number of peaks determined by somatic
mosaicism in blood is fewer than that observed in
other tissues, making the count of these not very
informative. To grade the mosaicism in this setting,
we calculated an MI by summing the area of all extra
peaks and dividing by the area of the major peak
(figure 4B). CAG repeat number and MI showed a
positive correlation (p5 0.0014) (figure 4C), confirm-
ing results obtained in skin and muscle tissues.21 We
then assessed whether the MI correlated to clinical
features of the disease. The MI significantly correlated
Figure 3 Clinical-genetic correlations
Number of CAG repeats is plotted vs disease onset (A), age when first required handrail (B), age when started using a cane
(C), and age when started using a wheelchair (D).
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inversely with age at onset of disease, but correlation
failed to reach significance for other clinical features
and ADL milestones (figures 4D and e-6).
DISCUSSION Phase 2 clinical trials have been con-
ducted in world-leading clinical centers for SBMA
in Japan, Europe, and the United States.14,15,22
However, in order to conduct any future phase 3
clinical trials, and to more efficiently translate research
findings to the clinic, it is clear that large cohorts of
patients and better defined information on disease
course and potential geographic- and ethnic-related
differences are needed.14,15 Therefore, we created the
first national register for SBMA in the United
Kingdom, where single medical centers are unlikely to
follow up more than 4 to 5 patients, and in this study,
we present the clinical and genetic information of
patients participating in this register.
The general features of our study population were
comparable to the 2 large previously published co-
horts, including age at weakness onset (43.4 years
in our study; 41 and 45.4 years in the US and Japa-
nese cohorts, respectively) and CAG repeat length
(46.03 repeats in our UK cohort; 46.6 and 46.7 in
the US and Japanese cohorts, respectively).3,4
The majority (87%) of participants are followed
up by a neurologist, but this could be attributable
to an overestimation bias, because the recruitment
of patients occurred by contacting all British consul-
tant neurologists through the Association of British
Neurologists.
Onset of muscle weakness most frequently occurred
in the lower limbs, in line with other studies, but we
noticed a lower frequency of initial bulbar involvement
than reported in the previous studies (6.7%, vs 13.8%
and 33% in Japanese and US studies).
When onset was asymmetrical, it occurred on the
dominant side in 71% of cases, which is similar to
69% previously reported.4 Of note, the increased use
of the dominant side has been suggested to have a role
in neuromuscular disorders; for example, asymmetry
favoring the dominant side has been shown in ALS.23
One in 3 of the patients in our study received an alter-
native diagnosis and a similar proportion of patients
underwent a muscle biopsy, showing a frequently com-
plex workup leading to the correct diagnosis. Beyond pri-
mary myopathies and other forms of motor neuron
disease, 2 patients received the diagnosis of Parkinson dis-
ease because of the presence of tremors. One in 10
patients received the genetic diagnosis before symptom
onset and this number is likely to be an underrepresenta-
tion, because 5 participants received the diagnosis before
genetic testing was available and a further 10 participants
less than 10 years after the discovery of the genetic cause.
The variability in impairment of ADL milestones
was high, but median age remarkably paralleled the
Figure 4 Analysis of CAG repeat somatic mosaicism
Sequence traces allow visualization of somatic mosaicism by analyzing the signal of a single T nucleotide 9 bases downstream of the repeat (A). Sequencing
after cloning shows loss of extra peaks, and further reamplification shows appearance only of peaks of smaller sizes than the major peak. Example of peak
area calculation performed on fragment analysis results in order to calculate the mosaicism index (MI) (B). MI is plotted with CAG repeat expansion size (C).
Age at onset is plotted vs both CAG expansion repeat size and MI (D).
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results reported in the Japanese study, with weakness
occurring at 44 years and bulbar deficits causing dys-
arthria and dysphagia and use of mobility aids becom-
ing necessary between 50 and 57 years of age. The
only value differing between the Japanese and our
cohort is the age at death (65 vs 79 years, respec-
tively). This difference could be attributable to the
fact that our study was conducted principally on liv-
ing patients participating in the UK National Register
for SBMA and only basic clinical-genetic informa-
tion, such as CAG repeats, date at onset, and date
at death, was used for deceased patients, thus making
the set of patients contributing to the age at death data
different from the rest. Indeed, while the size in our
study cohort was similar to the study from the Sobue
group in Japan, the repeat size in the subgroup of
deceased patients was smaller (43.6 vs 45.4), potentially
accounting for the observed age at death difference.
The cross-sectional analysis we conducted
confirmed—both by using a functional rating scale
and by asking for subjective disease impact—that
SBMA prevalently affects mobility at the outset to
then develop into upper limb- and bulbar-related dis-
abilities. Comparison of the results for the ALSFRS
score with a cross-sectional study performed in North
America19 confirms similar disease characteristics
independently of geographic differences.
Our association analysis between CAG repeats and
clinical features shows a significant inverse association
with age at onset and ADL mobility milestones. CAG
repeat number did not correlate with disease progression,
confirming previous observations by the Sobue group3
and indeed suggesting that the correlation with ADL
milestones principally reflects the effect on age at onset.
Age at death was the only clinical milestone differ-
ing between our population and the Japanese cohort,
and was the only one characterized by a different
CAG repeat number; this warrants consideration of
CAG repeat length in randomization and in study
outcome analysis.
Somatic instability has been described in SBMA
and in the majority of CAG repeat disorders.7 We
sought to assess the degree of blood somatic mosai-
cism and to determine whether there was a correlation
with disease features, and indeed we found a correla-
tion with CAG expansion size and also an inverse
correlation with age at disease onset. Further studies
on larger numbers will be required to assess whether
the somatic mosaicism has an effect on age indepen-
dently from CAG expansion size.
Our study highlights important clinical features to be
considered in the care of patients with SBMA and when
planning clinical trials and interventions. A limitation of
our study is that it is based on interviews and is therefore
subject to recollection bias. Nonetheless, our data show
remarkable overlap of clinical features when analyzing
SBMA cohorts with different genetic and geographic
backgrounds. This finding is of utmost importance for
planning and developing future clinical trials. Indeed,
SBMA is a rare disorder, and to achieve the power to
detect potentially beneficial effects, future phase 2 and
3 randomized controlled clinical trials will have to be
conducted with a multicenter, international approach.
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